Asset
MIPASETAMAB UZOPTIRINE
ADC Therapeutics SA Common Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05389462 | phase1 | terminated | 2022-07-13 | 2025-04-17 | ADC Therapeutics S.A. | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors |
| NCT03700294 | phase1 | terminated | 2018-12-21 | 2019-12-11 | ADC Therapeutics S.A. | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.